董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Javier J. Rodriguez | 男 | Chief Executive Officer,Director | 53 | 329.84万美元 | 108.56 | 2024-04-10 |
| Barbara J. Desoer | 女 | Independent Director | 71 | 36.75万美元 | 1.60 | 2024-04-10 |
| Jason M. Hollar | 男 | Independent Director | 51 | 14.41万美元 | 0.35 | 2024-04-10 |
| Phyllis R. Yale | 女 | Independent Director | 66 | 33.00万美元 | 1.50 | 2024-04-10 |
| Gregory J. Moore | 男 | Independent Director | 59 | 29.50万美元 | 0.47 | 2024-04-10 |
| Wendy L. Schoppert | -- | director | -- | 未披露 | 0.08 | 2024-04-10 |
| Dennis W. Pullin | -- | Director | -- | 未披露 | 未持股 | 2024-04-10 |
| Pamela M. Arway | 女 | Independent Director,Board Chair | 70 | 47.00万美元 | 2.39 | 2024-04-10 |
| Charles G. Berg | 男 | Independent Director | 66 | 28.50万美元 | 2.53 | 2024-04-10 |
| John M. Nehra | 男 | Independent Director | 75 | 34.55万美元 | 7.83 | 2024-04-10 |
| Adam H. Schechter | 男 | Independent Director | 59 | 3.79万美元 | 0.26 | 2024-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Javier J. Rodriguez | 男 | Chief Executive Officer,Director | 53 | 329.84万美元 | 108.56 | 2024-04-10 |
| Kathleen A. Waters | 女 | Chief Legal and Public Affairs Officer | 56 | 362.40万美元 | 7.30 | 2024-04-10 |
| James O. Hearty | 男 | Chief Compliance Officer | 55 | 174.54万美元 | 1.47 | 2024-04-10 |
| Christopher Berry | 男 | Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2024-04-10 |
| Joel Ackerman | 男 | Chief Financial Officer and Treasurer | 58 | 474.08万美元 | 18.10 | 2024-04-10 |
| Michael D. Staffieri | 男 | Chief Operating Officer, DaVita Kidney Care | 50 | 694.07万美元 | 26.18 | 2024-04-10 |
董事简历
中英对照 | 中文 | 英文- Javier J. Rodriguez
-
Javier J. Rodriguez，2012年2月成为公司总裁。2006年4月至2012年2月期间担任高级副总裁。2003年12月至2006年4月期间担任副总裁，负责价值管理业务。1999年8月至2003年12月期间，他曾担任偿付合约副总裁。1998年7月至1999年8月期间，担任区域财务分析是。加入公司之前，他曾于1995-1996年期间工作于Baxter Healthcare Corporation，负责财务工作。他 还曾的那人过墨西哥地区CBS Marketing Inc.业务主管。
Javier J. Rodriguez,has served as DAVITA INC. CEO since June 2019. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as DAVITA INC. President. From April 2006 through February 2012, he served as DAVITA INC. Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Since June 2020, Mr. Rodriguez has been a member of the Board of Directors of Gilead Sciences, Inc., a research-based pharmaceutical company. - Javier J. Rodriguez，2012年2月成为公司总裁。2006年4月至2012年2月期间担任高级副总裁。2003年12月至2006年4月期间担任副总裁，负责价值管理业务。1999年8月至2003年12月期间，他曾担任偿付合约副总裁。1998年7月至1999年8月期间，担任区域财务分析是。加入公司之前，他曾于1995-1996年期间工作于Baxter Healthcare Corporation，负责财务工作。他 还曾的那人过墨西哥地区CBS Marketing Inc.业务主管。
- Javier J. Rodriguez,has served as DAVITA INC. CEO since June 2019. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as DAVITA INC. President. From April 2006 through February 2012, he served as DAVITA INC. Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Since June 2020, Mr. Rodriguez has been a member of the Board of Directors of Gilead Sciences, Inc., a research-based pharmaceutical company.
- Barbara J. Desoer
-
Barbara J. Desoer，自2015年10月起担任公司董事。Desoer现任Citibank, N.A。（Citigroup Inc. 一家全资子公司，一家多元全球金融服务公司）首席执行官和董事，自2014年4月起担任该职位。Desoer之前从2013年10月到2014年4月担任Citibank, N.A。首席运营官。除了担任首席执行官之外，Desoer还领导Citigroup的综合资本分析和评估过程。加入Citibank之前，Desoer在Bank of America（一家多元全球金融服务公司）任职了35年，最近的职位是担任Bank of America Home Loans总裁，领导Countrywide（美国最大的抵押贷款发起人和服务商）的整合。在Bank of America任职之前，Desoer担任全球技术&运营主管（一个国际市场支持职位，领导英国、亚洲和拉丁美洲的小组）。她还曾担任消费产品总裁。她现任the University of California at Berkeley客座董事。Desoer还曾担任多个非盈利和私人控股公司董事。
Barbara J. Desoer,served as the CEO and a member of the Board of Directors of Citibank, N.A., a wholly owned subsidiary of Citigroup, Inc., a diversified global financial services company, both positions she held from April 2014 through April 2019, and COO of Citibank, N.A. from October 2013 to April 2014. Prior to Citibank, N.A., Ms. Desoer spent 35 years at Bank of America, a diversified global financial services company, most recently as President, Bank of America Home Loans, where she led the integration of Countrywide, the largest mortgage originator and servicer in the United States. In previous Bank of America roles, Ms. Desoer served as a Global Technology & Operations executive, an international market-focused position leading teams in the United Kingdom, Asia and Latin America, and President, Consumer Products. Since April 2019, Ms. Desoer has served as Chair of Citibank, N.A. and as a director of Citigroup, Inc. She serves on the Advisory Board of InStride. Ms. Desoer also has served on the board of directors of various non-profit and privately held corporations. - Barbara J. Desoer，自2015年10月起担任公司董事。Desoer现任Citibank, N.A。（Citigroup Inc. 一家全资子公司，一家多元全球金融服务公司）首席执行官和董事，自2014年4月起担任该职位。Desoer之前从2013年10月到2014年4月担任Citibank, N.A。首席运营官。除了担任首席执行官之外，Desoer还领导Citigroup的综合资本分析和评估过程。加入Citibank之前，Desoer在Bank of America（一家多元全球金融服务公司）任职了35年，最近的职位是担任Bank of America Home Loans总裁，领导Countrywide（美国最大的抵押贷款发起人和服务商）的整合。在Bank of America任职之前，Desoer担任全球技术&运营主管（一个国际市场支持职位，领导英国、亚洲和拉丁美洲的小组）。她还曾担任消费产品总裁。她现任the University of California at Berkeley客座董事。Desoer还曾担任多个非盈利和私人控股公司董事。
- Barbara J. Desoer,served as the CEO and a member of the Board of Directors of Citibank, N.A., a wholly owned subsidiary of Citigroup, Inc., a diversified global financial services company, both positions she held from April 2014 through April 2019, and COO of Citibank, N.A. from October 2013 to April 2014. Prior to Citibank, N.A., Ms. Desoer spent 35 years at Bank of America, a diversified global financial services company, most recently as President, Bank of America Home Loans, where she led the integration of Countrywide, the largest mortgage originator and servicer in the United States. In previous Bank of America roles, Ms. Desoer served as a Global Technology & Operations executive, an international market-focused position leading teams in the United Kingdom, Asia and Latin America, and President, Consumer Products. Since April 2019, Ms. Desoer has served as Chair of Citibank, N.A. and as a director of Citigroup, Inc. She serves on the Advisory Board of InStride. Ms. Desoer also has served on the board of directors of various non-profit and privately held corporations.
- Jason M. Hollar
-
Jason M. Hollar，他于2016年10月被任命为现任职务，并自2014年10月以来开始担任公司的高级财务副总裁。加入公司之前，他曾任职Delphi Automotive PLC（从2013年12月到2014年9月），担任副总裁兼公司总会计师，也曾担任Powertrain Systems、Delphi Europe、Middle East and Africa的首席财务官（从2011年4月到2013年11月）。
Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Prior to that, Mr. Hollar served as the Executive Vice President and Chief Financial Officer of Tenneco Inc. ("Tenneco") from July 2018. From June 2017 to June 2018, Mr. Hollar was Senior Vice President Finance at Tenneco. Prior to that, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018. - Jason M. Hollar，他于2016年10月被任命为现任职务，并自2014年10月以来开始担任公司的高级财务副总裁。加入公司之前，他曾任职Delphi Automotive PLC（从2013年12月到2014年9月），担任副总裁兼公司总会计师，也曾担任Powertrain Systems、Delphi Europe、Middle East and Africa的首席财务官（从2011年4月到2013年11月）。
- Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Prior to that, Mr. Hollar served as the Executive Vice President and Chief Financial Officer of Tenneco Inc. ("Tenneco") from July 2018. From June 2017 to June 2018, Mr. Hollar was Senior Vice President Finance at Tenneco. Prior to that, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018.
- Phyllis R. Yale
-
Phyllis R. Yale自2016年7月起担任DaVita Inc.的董事之一。Yale女士自2010年7月起担任Bain＆Company，Inc.的顾问合伙人。“ Bain”是一家全球管理咨询公司。Bain从1987年至2010年7月，是建立Bain医疗保健业务的领导者。耶鲁女士在Bain任职期间，与医疗保健付款人，医疗服务提供者和医疗设备公司合作，并经常为世界领先的私募股权公司就其在医疗保健领域的投资提供建议。她曾担任卫生保健领域多家公共和私人公司的董事会成员，目前担任马萨诸塞州Blue Cross Blue Shield董事会主席，该组织总部位于美国马萨诸塞州，是一家非营利性健康计划。波士顿耶鲁女士曾担任美国长期医疗保健服务提供商Kindred Healthcare，Inc.的董事会主席，从2010年1月至2018年7月，她是一家私人专科医院National Surgical Hospitals的董事。运营商，以及ValueOptions，Inc.的董事，ValueOptions，Inc.是一家专注于身心健康和康复的健康改善公司，于2014年与Beacon Health Strategies合并。
Phyllis R. Yale,has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain's healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world's leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company, and since 2014 has served as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts ("BCBS MA"). Ms. Yale previously served as Chair of the BCBS MA Board of Directors from 2014 to 2019 and Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018. - Phyllis R. Yale自2016年7月起担任DaVita Inc.的董事之一。Yale女士自2010年7月起担任Bain＆Company，Inc.的顾问合伙人。“ Bain”是一家全球管理咨询公司。Bain从1987年至2010年7月，是建立Bain医疗保健业务的领导者。耶鲁女士在Bain任职期间，与医疗保健付款人，医疗服务提供者和医疗设备公司合作，并经常为世界领先的私募股权公司就其在医疗保健领域的投资提供建议。她曾担任卫生保健领域多家公共和私人公司的董事会成员，目前担任马萨诸塞州Blue Cross Blue Shield董事会主席，该组织总部位于美国马萨诸塞州，是一家非营利性健康计划。波士顿耶鲁女士曾担任美国长期医疗保健服务提供商Kindred Healthcare，Inc.的董事会主席，从2010年1月至2018年7月，她是一家私人专科医院National Surgical Hospitals的董事。运营商，以及ValueOptions，Inc.的董事，ValueOptions，Inc.是一家专注于身心健康和康复的健康改善公司，于2014年与Beacon Health Strategies合并。
- Phyllis R. Yale,has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain's healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world's leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company, and since 2014 has served as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts ("BCBS MA"). Ms. Yale previously served as Chair of the BCBS MA Board of Directors from 2014 to 2019 and Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018.
- Gregory J. Moore
-
Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to April 2023, where he led Microsoft's health and life sciences research and product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. Since April 2023, Dr. Moore has served as a director of Olink Holding AB, a biotechnology company focused on proteomics. From 2019 until its merger with Baxter International Inc. in 2021, Dr. Moore was a member of the Board of Directors of Hill-Rom Holdings, Inc., a medical technology provider. - Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
- Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to April 2023, where he led Microsoft's health and life sciences research and product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. Since April 2023, Dr. Moore has served as a director of Olink Holding AB, a biotechnology company focused on proteomics. From 2019 until its merger with Baxter International Inc. in 2021, Dr. Moore was a member of the Board of Directors of Hill-Rom Holdings, Inc., a medical technology provider.
- Wendy L. Schoppert
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Dennis W. Pullin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Pamela M. Arway
-
Pamela M. Arway，2010年5月起担任Hershey董事。她是治理委员会主席，并且是审计委员会和执行委员会成员。此前她曾在位于纽约的美国运通公司（一家全球支付、网络和旅行公司）及其子公司担任各种职位。2005年10月至2008年1月期间曾担任美国运通国际有限公司新加坡公司总裁，负责日本/亚太/澳大利亚地区业务；2004年12月至2005年10月期间担任位于澳大利亚悉尼的美国运通澳大利亚有限公司CEO；2000年7月至2004年12月期间，她曾担任美国运通公司执行副总裁和总经理，负责北美地区公司传送业务。她在美国运通公司工作的21年期间，她拥有了金融、市场、国际业务、政府事务、消费品和人力资源方面的经验。2009年7月起担任DaVita HealthCare Partners, Inc.董事。她拥有纽芬兰纪念大学语言学学士学位和加拿大安大略金斯顿皇后大学工商管理硕士学位。
Pamela M. Arway,served in a number of capacities during her 21-year career with the American Express Company, Inc., a publicly held global payments, network and travel company, until her retirement in 2008. Ms. Arway served as president, Japan/Asia Pacific/Australia Region, American Express International, Inc., Singapore from October 2005 to January 2008. From December 2004 to October 2005, Ms. Arway served as chief executive officer, American Express Australia Ltd., Sydney, Australia. From July 2000 to December 2004, Ms. Arway served as executive vice president and general manager, Corporate Travel North America, American Express Company, Inc. Ms. Arway has been a director of The Hershey Company, a publicly held company, since May 2010 and has been a director of DaVita Inc., a publicly held company, since May 2009. Ms. Arway also served as a director of Carlson Companies, Inc., a family-owned corporate travel management and private capital company, from May 2019 to July 2021.Ms. Arway holds a bachelor's degree in languages from Memorial University of Newfoundland and a master's degree in business administration from Queen's University, Kingston, Ontario, Canada. - Pamela M. Arway，2010年5月起担任Hershey董事。她是治理委员会主席，并且是审计委员会和执行委员会成员。此前她曾在位于纽约的美国运通公司（一家全球支付、网络和旅行公司）及其子公司担任各种职位。2005年10月至2008年1月期间曾担任美国运通国际有限公司新加坡公司总裁，负责日本/亚太/澳大利亚地区业务；2004年12月至2005年10月期间担任位于澳大利亚悉尼的美国运通澳大利亚有限公司CEO；2000年7月至2004年12月期间，她曾担任美国运通公司执行副总裁和总经理，负责北美地区公司传送业务。她在美国运通公司工作的21年期间，她拥有了金融、市场、国际业务、政府事务、消费品和人力资源方面的经验。2009年7月起担任DaVita HealthCare Partners, Inc.董事。她拥有纽芬兰纪念大学语言学学士学位和加拿大安大略金斯顿皇后大学工商管理硕士学位。
- Pamela M. Arway,served in a number of capacities during her 21-year career with the American Express Company, Inc., a publicly held global payments, network and travel company, until her retirement in 2008. Ms. Arway served as president, Japan/Asia Pacific/Australia Region, American Express International, Inc., Singapore from October 2005 to January 2008. From December 2004 to October 2005, Ms. Arway served as chief executive officer, American Express Australia Ltd., Sydney, Australia. From July 2000 to December 2004, Ms. Arway served as executive vice president and general manager, Corporate Travel North America, American Express Company, Inc. Ms. Arway has been a director of The Hershey Company, a publicly held company, since May 2010 and has been a director of DaVita Inc., a publicly held company, since May 2009. Ms. Arway also served as a director of Carlson Companies, Inc., a family-owned corporate travel management and private capital company, from May 2019 to July 2021.Ms. Arway holds a bachelor's degree in languages from Memorial University of Newfoundland and a master's degree in business administration from Queen's University, Kingston, Ontario, Canada.
- Charles G. Berg
-
Charles G. Berg自2022年1月起担任Government Business of Cigna总裁。2016年11月至2017年12月，他担任DaVita Medical Group“DMG”（DaVita的前综合医疗保健业务）的执行主席。从2007年3月开始一直担任公司的董事。从2008年1月到2010年12月，Berg先生担任WellCare Health Plans, Inc. （WellCare）的执行主席兼董事会董事，这是一家为政府资助医疗保健计划提供管理式照护服务的供应商。从2011年1月到2013年5月，Berg先生担任WellCare的董事会非执行主席。从2007年1月到2009年4月，Berg先生担任Welsh, Carson, Anderson & Stowe的高级顾问，该公司是一家私人股权公司。从1998年4月到2004年7月，Berg先生担任过Oxford Health Plans, Inc.（Oxford）的多个管理层职位，这是一家健康福利计划的提供商，包括从2002年11月到2004年7月担任首席执行官，2004年7月Oxford被UnitedHealth Group收购，从2001年3月到2002年11月担任总裁兼首席运营官，并从1998年4月到2001年3月担任医疗服务部的执行副总裁。从2004年7月到2006年9月，Berg先生担任UnitedHealth Group的执行官，主要负责整合Oxford的业务。
Charles G. Berg,has served as a Senior Advisor for The Cigna Group ("Cigna"), a global health service company, since January 2023, and served as President of U.S. Government Business and Senior Advisor for Cigna from January 2022 to January 2023. Mr. Berg served as Executive Chair of DaVita Medical Group ("DMG"), DaVita's former integrated healthcare business, from November 2016 until December 2017. From 2008 to 2013, Mr. Berg served as Executive Chair of WellCare Health Plans, Inc. ("WellCare"), a provider of managed care services for government-sponsored healthcare programs. Mr. Berg served as Non-Executive Chair of the Board of Directors of WellCare from January 2011 until May 2013. From January 2007 to April 2009, Mr. Berg was a Senior Advisor to Welsh, Carson, Anderson & Stowe, a private equity firm. From April 1998 to July 2004, Mr. Berg held various executive positions, including Executive Vice President - Medical Delivery, President and Chief Operating Officer ("COO") with Oxford Health Plans, Inc. ("Oxford"), a health benefit plan provider. He was the CEO when Oxford was acquired by UnitedHealth Group. He then became an executive of UnitedHealth Group and was primarily responsible for integrating the Oxford business. Mr. Berg also currently serves as a member of the Operating Council & Senior Advisory Board of Consonance Capital Partners, a private equity firm. - Charles G. Berg自2022年1月起担任Government Business of Cigna总裁。2016年11月至2017年12月，他担任DaVita Medical Group“DMG”（DaVita的前综合医疗保健业务）的执行主席。从2007年3月开始一直担任公司的董事。从2008年1月到2010年12月，Berg先生担任WellCare Health Plans, Inc. （WellCare）的执行主席兼董事会董事，这是一家为政府资助医疗保健计划提供管理式照护服务的供应商。从2011年1月到2013年5月，Berg先生担任WellCare的董事会非执行主席。从2007年1月到2009年4月，Berg先生担任Welsh, Carson, Anderson & Stowe的高级顾问，该公司是一家私人股权公司。从1998年4月到2004年7月，Berg先生担任过Oxford Health Plans, Inc.（Oxford）的多个管理层职位，这是一家健康福利计划的提供商，包括从2002年11月到2004年7月担任首席执行官，2004年7月Oxford被UnitedHealth Group收购，从2001年3月到2002年11月担任总裁兼首席运营官，并从1998年4月到2001年3月担任医疗服务部的执行副总裁。从2004年7月到2006年9月，Berg先生担任UnitedHealth Group的执行官，主要负责整合Oxford的业务。
- Charles G. Berg,has served as a Senior Advisor for The Cigna Group ("Cigna"), a global health service company, since January 2023, and served as President of U.S. Government Business and Senior Advisor for Cigna from January 2022 to January 2023. Mr. Berg served as Executive Chair of DaVita Medical Group ("DMG"), DaVita's former integrated healthcare business, from November 2016 until December 2017. From 2008 to 2013, Mr. Berg served as Executive Chair of WellCare Health Plans, Inc. ("WellCare"), a provider of managed care services for government-sponsored healthcare programs. Mr. Berg served as Non-Executive Chair of the Board of Directors of WellCare from January 2011 until May 2013. From January 2007 to April 2009, Mr. Berg was a Senior Advisor to Welsh, Carson, Anderson & Stowe, a private equity firm. From April 1998 to July 2004, Mr. Berg held various executive positions, including Executive Vice President - Medical Delivery, President and Chief Operating Officer ("COO") with Oxford Health Plans, Inc. ("Oxford"), a health benefit plan provider. He was the CEO when Oxford was acquired by UnitedHealth Group. He then became an executive of UnitedHealth Group and was primarily responsible for integrating the Oxford business. Mr. Berg also currently serves as a member of the Operating Council & Senior Advisory Board of Consonance Capital Partners, a private equity firm.
- John M. Nehra
-
John M. Nehra，2000年11月起担任公司董事。1989开始与New Enterprise Associates（NEA）（一家风投公司）合作，包括1993年起担任它的几家附属风投公司总法律顾问。1989年起他还担任Catalyst Ventures（一家风投公司）管理普通合伙人。目前就职于数个NEA资产组合公司董事会。
John M. Nehra,was from 1989 until his retirement in August 2014, affiliated with New Enterprise Associates ("NEA"), a venture capital firm, including, from 1993 until his retirement, as General Partner of several of its affiliated venture capital limited partnerships. After his retirement in August 2014, Mr. Nehra remained a retired Special Partner with NEA and continued serving on the board of directors of a number of NEA's portfolio companies. Mr. Nehra also served as Managing General Partner of Catalyst Ventures, an affiliate of NEA, from 1989 to 2013. Since 2021, Mr. Nehra has served as a member of the Board of CVRx, Inc., a commercial-stage medical device company. - John M. Nehra，2000年11月起担任公司董事。1989开始与New Enterprise Associates（NEA）（一家风投公司）合作，包括1993年起担任它的几家附属风投公司总法律顾问。1989年起他还担任Catalyst Ventures（一家风投公司）管理普通合伙人。目前就职于数个NEA资产组合公司董事会。
- John M. Nehra,was from 1989 until his retirement in August 2014, affiliated with New Enterprise Associates ("NEA"), a venture capital firm, including, from 1993 until his retirement, as General Partner of several of its affiliated venture capital limited partnerships. After his retirement in August 2014, Mr. Nehra remained a retired Special Partner with NEA and continued serving on the board of directors of a number of NEA's portfolio companies. Mr. Nehra also served as Managing General Partner of Catalyst Ventures, an affiliate of NEA, from 1989 to 2013. Since 2021, Mr. Nehra has served as a member of the Board of CVRx, Inc., a commercial-stage medical device company.
- Adam H. Schechter
-
Adam H. Schechter自2013年4月1日起担任公司董事，自2019年11月1日起担任公司总裁兼首席执行官。在此之前，Schechter先生是默克公司的执行副总裁， 从2010年到2018年，他是默克公司执行委员会以及药品和疫苗运营委员会的成员。 他于2019年1月至2019年7月担任默克（Merck）首席执行官的特别顾问。他曾担任默克（Merck）全球人类健康部总裁，该部门于2010年至2018年包括该公司的全球制药和疫苗业务。 Schechter先生于2007年至2010年担任全球制药业务总裁。
Adam H. Schechter,has served as a director of the Company since April 2013, President and Chief Executive Officer of the Company since November 2019, and Chairman of the Board since May 2020. Prior to that, Mr. Schechter was President of Global Human Health and an Executive Vice President of Merck & Co., Inc., a pharmaceutical company, from 2010 to 2018, where he was a member of Merck's executive committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter holds a bachelor's degree in biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from La Salle University in 2021. - Adam H. Schechter自2013年4月1日起担任公司董事，自2019年11月1日起担任公司总裁兼首席执行官。在此之前，Schechter先生是默克公司的执行副总裁， 从2010年到2018年，他是默克公司执行委员会以及药品和疫苗运营委员会的成员。 他于2019年1月至2019年7月担任默克（Merck）首席执行官的特别顾问。他曾担任默克（Merck）全球人类健康部总裁，该部门于2010年至2018年包括该公司的全球制药和疫苗业务。 Schechter先生于2007年至2010年担任全球制药业务总裁。
- Adam H. Schechter,has served as a director of the Company since April 2013, President and Chief Executive Officer of the Company since November 2019, and Chairman of the Board since May 2020. Prior to that, Mr. Schechter was President of Global Human Health and an Executive Vice President of Merck & Co., Inc., a pharmaceutical company, from 2010 to 2018, where he was a member of Merck's executive committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter holds a bachelor's degree in biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from La Salle University in 2021.
高管简历
中英对照 | 中文 | 英文- Javier J. Rodriguez
Javier J. Rodriguez，2012年2月成为公司总裁。2006年4月至2012年2月期间担任高级副总裁。2003年12月至2006年4月期间担任副总裁，负责价值管理业务。1999年8月至2003年12月期间，他曾担任偿付合约副总裁。1998年7月至1999年8月期间，担任区域财务分析是。加入公司之前，他曾于1995-1996年期间工作于Baxter Healthcare Corporation，负责财务工作。他 还曾的那人过墨西哥地区CBS Marketing Inc.业务主管。
Javier J. Rodriguez,has served as DAVITA INC. CEO since June 2019. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as DAVITA INC. President. From April 2006 through February 2012, he served as DAVITA INC. Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Since June 2020, Mr. Rodriguez has been a member of the Board of Directors of Gilead Sciences, Inc., a research-based pharmaceutical company.- Javier J. Rodriguez，2012年2月成为公司总裁。2006年4月至2012年2月期间担任高级副总裁。2003年12月至2006年4月期间担任副总裁，负责价值管理业务。1999年8月至2003年12月期间，他曾担任偿付合约副总裁。1998年7月至1999年8月期间，担任区域财务分析是。加入公司之前，他曾于1995-1996年期间工作于Baxter Healthcare Corporation，负责财务工作。他 还曾的那人过墨西哥地区CBS Marketing Inc.业务主管。
- Javier J. Rodriguez,has served as DAVITA INC. CEO since June 2019. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as DAVITA INC. President. From April 2006 through February 2012, he served as DAVITA INC. Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Since June 2020, Mr. Rodriguez has been a member of the Board of Directors of Gilead Sciences, Inc., a research-based pharmaceutical company.
- Kathleen A. Waters
Kathleen A. Waters于2016年4月加入公司担任首席法务官。加入公司之前，Waters从2015年4月到2016年3月担任Health Net, Inc.（一家公开上市管理医疗组织）高级副总裁、总法律顾问和秘书。她从2003年到2005年担任Morgan, Lewis & Bockius LLP诉讼实践部门合伙人。她还曾担任该公司位于洛杉矶的诉讼集团领导人以及医疗保健集团主管。在此之前，Waters是洛杉矶Brobeck, Phleger & Harrison LLP合伙人。
Kathleen A. Waters,became DAVITA INC. CLO in May 2016, overseeing all legal and regulatory functions for the enterprise. In February 2021, Ms. Waters became DAVITA INC. Chief Legal and Public Affairs Officer as she also took over responsibility for federal government affairs. Prior to joining the Company, Ms. Waters was Senior Vice President, General Counsel and Secretary of Health Net, Inc., a publicly traded managed care organization, from 2015 to 2016. Prior to Health Net, Inc., Ms. Waters was a Partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015, where she was the co-chair of the healthcare group. Prior to Morgan Lewis, Ms. Waters was in private practice at various law firms since 1994.- Kathleen A. Waters于2016年4月加入公司担任首席法务官。加入公司之前，Waters从2015年4月到2016年3月担任Health Net, Inc.（一家公开上市管理医疗组织）高级副总裁、总法律顾问和秘书。她从2003年到2005年担任Morgan, Lewis & Bockius LLP诉讼实践部门合伙人。她还曾担任该公司位于洛杉矶的诉讼集团领导人以及医疗保健集团主管。在此之前，Waters是洛杉矶Brobeck, Phleger & Harrison LLP合伙人。
- Kathleen A. Waters,became DAVITA INC. CLO in May 2016, overseeing all legal and regulatory functions for the enterprise. In February 2021, Ms. Waters became DAVITA INC. Chief Legal and Public Affairs Officer as she also took over responsibility for federal government affairs. Prior to joining the Company, Ms. Waters was Senior Vice President, General Counsel and Secretary of Health Net, Inc., a publicly traded managed care organization, from 2015 to 2016. Prior to Health Net, Inc., Ms. Waters was a Partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015, where she was the co-chair of the healthcare group. Prior to Morgan Lewis, Ms. Waters was in private practice at various law firms since 1994.
- James O. Hearty
James O. Hearty，于2018年3月成为DAVITA INC.的CCO.2015年9月至2018年3月，他担任DAVITA INC.高级副总裁兼肾脏护理首席执行官，在此之前，2012年2月至2015年8月，他曾担任副总裁兼副总法律顾问。在加入DAVITA INC.之前，他曾在美国司法部（“DOJ”）担任检察官和审判律师14年。他开始于华盛顿特区司法部民事司，四年后成为科罗拉多州U.S. Attorney's Office的助理美国检察官。Hearty先生曾在U.S. Attorney's Office担任过多个领导职位，包括刑事司副司长。Hearty先生也是Urban Peak的董事会成员，这是一家Denver non-profit，为无家可归的年轻人提供服务。
James O. Hearty,became DAVITA INC. CCO in March 2018. From September 2015 to March 2018, he served as DAVITA INC. Senior Vice President and CCO - Kidney Care, and prior to that, from February 2012 to August 2015, he served as Vice President, Associate General Counsel. Prior to joining DAVITA INC., he was a prosecutor and trial attorney with the U.S. Department of Justice ("DOJ") for 14 years. He started in the Civil Division of the DOJ in Washington D.C. and four years later became an Assistant U.S. Attorney in the U.S. Attorney's Office for the District of Colorado. Mr. Hearty held several leadership positions at the U.S. Attorney's Office, including Deputy Chief of the criminal division. Mr. Hearty also serves on the board of Urban Peak, a Denver non-profit that serves youth experiencing homelessness.- James O. Hearty，于2018年3月成为DAVITA INC.的CCO.2015年9月至2018年3月，他担任DAVITA INC.高级副总裁兼肾脏护理首席执行官，在此之前，2012年2月至2015年8月，他曾担任副总裁兼副总法律顾问。在加入DAVITA INC.之前，他曾在美国司法部（“DOJ”）担任检察官和审判律师14年。他开始于华盛顿特区司法部民事司，四年后成为科罗拉多州U.S. Attorney's Office的助理美国检察官。Hearty先生曾在U.S. Attorney's Office担任过多个领导职位，包括刑事司副司长。Hearty先生也是Urban Peak的董事会成员，这是一家Denver non-profit，为无家可归的年轻人提供服务。
- James O. Hearty,became DAVITA INC. CCO in March 2018. From September 2015 to March 2018, he served as DAVITA INC. Senior Vice President and CCO - Kidney Care, and prior to that, from February 2012 to August 2015, he served as Vice President, Associate General Counsel. Prior to joining DAVITA INC., he was a prosecutor and trial attorney with the U.S. Department of Justice ("DOJ") for 14 years. He started in the Civil Division of the DOJ in Washington D.C. and four years later became an Assistant U.S. Attorney in the U.S. Attorney's Office for the District of Colorado. Mr. Hearty held several leadership positions at the U.S. Attorney's Office, including Deputy Chief of the criminal division. Mr. Hearty also serves on the board of Urban Peak, a Denver non-profit that serves youth experiencing homelessness.
- Christopher Berry
Christopher Berry，他于2022年8月至2023年8月在Sonder Holdings Inc.（“Sonder”）担任高级副总裁兼首席会计官，这是一家上市的酒店公司。他还曾担任Sonder的临时首席财务官（从2023年1月到2023年3月）。在加入Sonder之前，Berry先生在Alaska Air Group, Inc.（一家上市的航空控股公司）担任各种职务，从2017年2月到2022年4月担任副总裁、公司财务总监和首席会计官，从2014年2月到2017年2月担任会计总经理、公司财务总监和首席会计官，从2010年10月到2014年2月担任投资者关系总经理，以及董事。2005年3月至2010年10月担任财务报告和会计。他持有the University of Louisiana Monroe的工商管理学士学位和华盛顿州的注册会计师执照。
Christopher Berry,join the Company after holding the positions of Senior Vice President and Chief Accounting Officer at Sonder Holdings Inc. ("Sonder"), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder's Interim Principal Financial Officer from January 2023 to March 2023. Prior to joining Sonder, Mr. Berry held various roles at Alaska Air Group, Inc., a publicly traded airline holding company, serving as Vice President, Corporate Controller, and Chief Accounting Officer from February 2017 to April 2022, Managing Director of Accounting, Corporate Controller and Principal Accounting Officer from February 2014 to February 2017, Managing Director, Investor Relations from October 2010 to February 2014, and Director, Financial Reporting and Accounting from March 2005 to October 2010. Mr. Berry holds a Bachelor of Business Administration from the University of Louisiana Monroe and a CPA license in the State of Washington.- Christopher Berry，他于2022年8月至2023年8月在Sonder Holdings Inc.（“Sonder”）担任高级副总裁兼首席会计官，这是一家上市的酒店公司。他还曾担任Sonder的临时首席财务官（从2023年1月到2023年3月）。在加入Sonder之前，Berry先生在Alaska Air Group, Inc.（一家上市的航空控股公司）担任各种职务，从2017年2月到2022年4月担任副总裁、公司财务总监和首席会计官，从2014年2月到2017年2月担任会计总经理、公司财务总监和首席会计官，从2010年10月到2014年2月担任投资者关系总经理，以及董事。2005年3月至2010年10月担任财务报告和会计。他持有the University of Louisiana Monroe的工商管理学士学位和华盛顿州的注册会计师执照。
- Christopher Berry,join the Company after holding the positions of Senior Vice President and Chief Accounting Officer at Sonder Holdings Inc. ("Sonder"), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder's Interim Principal Financial Officer from January 2023 to March 2023. Prior to joining Sonder, Mr. Berry held various roles at Alaska Air Group, Inc., a publicly traded airline holding company, serving as Vice President, Corporate Controller, and Chief Accounting Officer from February 2017 to April 2022, Managing Director of Accounting, Corporate Controller and Principal Accounting Officer from February 2014 to February 2017, Managing Director, Investor Relations from October 2010 to February 2014, and Director, Financial Reporting and Accounting from March 2005 to October 2010. Mr. Berry holds a Bachelor of Business Administration from the University of Louisiana Monroe and a CPA license in the State of Washington.
- Joel Ackerman
Joel Ackerman自2008年9月以来担任公司的董事。他自2010年10月以来担任Champions Oncology, Inc.（OTC：CSBR）（从事开发先进技术解决方案和服务，促使肿瘤药物开发和使用个性化的公司）的首席执行官和董事。之前，他从2009年11月至2010年7月是Acumen Fund（非盈利的全球风险基金，利用创业方法解决贫困问题）的资深投资组合研究员，从1998年1月至2008年9月是全球私人股本公司Warburg Pincus LLC（"Warburg Pincus"）的董事总经理和医疗服务集团的主管。
Joel Ackerman,has served as the Chairman of the Board of the Company since January 2017. Previously, Mr. Ackerman served as Chief Executive Officer and a director of the Company from October 2010 to January 2017. Mr Ackerman is currently the Chief Financial Officer of Davita, Inc. Mr. Ackerman received a bachelor's degree from Columbia University,where he graduated summa cum laude in 1988, and a master's degree in Physics from Harvard University in 1990. From 1990 to 1993, Mr. Ackerman was an associate with Mercer Management Consulting, a global strategy consulting firm. From 1993 to 2008, Mr. Ackerman was employed by Warburg Pincus, LLC, a global private equity investment firm. There, Mr. Ackerman served in various capacities including Managing Director, Head of Healthcare Services, and as a member of the firm's executive management team. During 2010, Mr. Ackerman served as a senior portfolio fellow with Acumen Fund, a non-profit global venture fund that Champions Oncology, Inc. es entrepreneurial approaches to address global poverty.- Joel Ackerman自2008年9月以来担任公司的董事。他自2010年10月以来担任Champions Oncology, Inc.（OTC：CSBR）（从事开发先进技术解决方案和服务，促使肿瘤药物开发和使用个性化的公司）的首席执行官和董事。之前，他从2009年11月至2010年7月是Acumen Fund（非盈利的全球风险基金，利用创业方法解决贫困问题）的资深投资组合研究员，从1998年1月至2008年9月是全球私人股本公司Warburg Pincus LLC（"Warburg Pincus"）的董事总经理和医疗服务集团的主管。
- Joel Ackerman,has served as the Chairman of the Board of the Company since January 2017. Previously, Mr. Ackerman served as Chief Executive Officer and a director of the Company from October 2010 to January 2017. Mr Ackerman is currently the Chief Financial Officer of Davita, Inc. Mr. Ackerman received a bachelor's degree from Columbia University,where he graduated summa cum laude in 1988, and a master's degree in Physics from Harvard University in 1990. From 1990 to 1993, Mr. Ackerman was an associate with Mercer Management Consulting, a global strategy consulting firm. From 1993 to 2008, Mr. Ackerman was employed by Warburg Pincus, LLC, a global private equity investment firm. There, Mr. Ackerman served in various capacities including Managing Director, Head of Healthcare Services, and as a member of the firm's executive management team. During 2010, Mr. Ackerman served as a senior portfolio fellow with Acumen Fund, a non-profit global venture fund that Champions Oncology, Inc. es entrepreneurial approaches to address global poverty.
- Michael D. Staffieri
Michael D. Staffieri成为DaVita公司。DaVita Kidney Care首席运营官，2014年3月。2011年7月至2014年3月，他担任肾脏护理高级副总裁。Staffieri先生最初于2000年7月加入DaVita Inc.，自那时起担任多个不同的职位，包括从2008年3月到2011年7月担任DaVita Inc.的运营和新中心开发副总裁。在加入DaVita Inc.之前，他曾担任Arthur Andersen LLP的顾问（从1999年到2000年）。
Michael D. Staffieri,became DAVITA INC. COO, DaVita Kidney Care, in March 2014. From July 2011 to March 2014, he served as a Senior Vice President, Kidney Care. Mr. Staffieri initially joined DAVITA INC. in July 2000 and served in several different roles since that time, including as DAVITA INC. Vice President of Operations and New Center Development from March 2008 to July 2011. Prior to joining DAVITA INC., Mr. Staffieri worked as a consultant for Arthur Andersen LLP from 1999 to 2000.- Michael D. Staffieri成为DaVita公司。DaVita Kidney Care首席运营官，2014年3月。2011年7月至2014年3月，他担任肾脏护理高级副总裁。Staffieri先生最初于2000年7月加入DaVita Inc.，自那时起担任多个不同的职位，包括从2008年3月到2011年7月担任DaVita Inc.的运营和新中心开发副总裁。在加入DaVita Inc.之前，他曾担任Arthur Andersen LLP的顾问（从1999年到2000年）。
- Michael D. Staffieri,became DAVITA INC. COO, DaVita Kidney Care, in March 2014. From July 2011 to March 2014, he served as a Senior Vice President, Kidney Care. Mr. Staffieri initially joined DAVITA INC. in July 2000 and served in several different roles since that time, including as DAVITA INC. Vice President of Operations and New Center Development from March 2008 to July 2011. Prior to joining DAVITA INC., Mr. Staffieri worked as a consultant for Arthur Andersen LLP from 1999 to 2000.